OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
OS Therapies appointed Kerry Clem as Chief Commercial Officer and Frank Knuettel II as CFO, tasked with preparing U.S., U.K., and European launch infrastructure for lead asset Herlystic (OST-HER2) in osteosarcoma. Concurrent with the hires, the company disclosed its U.K. subsidiary has received over $3 million in non-dilutive VAT refunds with over $7 million in R&D tax credits accrued, earmarked for commercial manufacturing and Phase 3 work.
Key figures
- Ap deferral
- majority of outstanding AP delayed until Q2 2027
- Prior prv sale
- $220 million (August 2026 comparable)
- Vat refunds received
- $3 million
- Rd tax credits accrued
- $7 million
- Cno capital raised by knuettel
- $500 million career total
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.